FARMINGDALE, N.Y., July 30, 2020 (GLOBE NEWSWIRE) — Misonix, Inc. (Nasdaq: MSON), a provider of minimally invasive therapeutic ultrasonic medical devices and regenerative products that enhance clinical outcomes, today announced that it will be participating in the 40th Annual Canaccord Genuity Growth Conference. Misonix Chief Executive Officer, Stavros Vizirgianakis, along with Joe Dwyer, Misonix Chief Financial Officer, will be making a virtual company presentation on Wednesday, August 12th at 10:30 a.m. ET. Management will also be available to speak with institutional investors in one-on-one virtual meetings throughout the day on August 12th and 13th.
If you have questions about Misonix or are interested in conducting a conference call or meeting with management, please contact the Company’s investor relations firm, JCIR, at (212) 835-8500 or via email at mson@jcir.com.About Misonix, Inc.Misonix, Inc. (Nasdaq: MSON) designs, manufactures and markets minimally invasive ultrasonic medical devices used for precise bone sculpting, removal of soft and hard tumors and tissue debridement, primarily in the areas of neurosurgery, orthopedic surgery, plastic surgery, wound care and maxillo-facial surgery. The Company combined its SonicOne wound debridement application with its recently acquired TheraSkin product, a leading cellular skin substitute indicated for all wound treatments. The Company’s sales force operates as two divisions, Surgical (Neuro and Spine Applications) and Wound. At Misonix, Better Matters to us. That is why throughout the Company’s history, Misonix has maintained its commitment to medical technology innovation and the development of products that radically improve patient outcomes. Additional information is available on the Company’s web site at www.misonix.com.Contact:
Joe Dwyer
Chief Financial Officer
Misonix, Inc.
631-927-9113Norberto Aja, Jennifer Neuman
JCIR
212-835-8500 or mson@jcir.com
Bay Street News